Cellular and Molecular Pathology of Head and Neck Tumors

El‐Naggar, Adel K.

doi:10.1007/978-3-319-27601-4_3

Cited by 12 publications

(49 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salivary gland tumors (SGTs) are very rare and correspond to numerous histologic entities1 with considerable morphologic overlap that makes their diagnosis very challenging for pathologists. Secretory carcinoma (SC), formerly known as mammary analogue SC, is a newly recognized entity that resembles breast SC 2.…”

mentioning

confidence: 99%

Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors

Csanyi-Bastien¹,

Lanic

Beaussire³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Aims: Secretory carcinoma (SC) is characterized by ETV6 rearrangements, most often ETV6-NTRK3 fusion. Given its histologic overlap with other salivary gland tumors (SGTs), SCs can be difficult to diagnose without genetic confirmation. A recently developed pan‐TRK (tropomyosin receptor kinase) antibody shows promise for identifying tumors with NTRK (neurotrophic tyrosine kinase receptor 3) fusions. The aim of this study was to evaluate the utility of pan‐TRK immunohistochemistry in distinguishing SCs from mimics and selecting patients eligible for TRK inhibitor clinical trials. We examined whole‐tissue sections from 111 SGTs with molecular characterization, including 26 SCs (23 with ETV6-NTRK3 fusion and 3 with ETV6-RET fusion detected by ligation-dependent reverse transcription-polymerase chain reaction, next-generation sequencing and 85 non-SC SGTs (no ETV6-NTRK3 fusion). Immunohistochemistry was performed with a pan‐TRK rabbit monoclonal antibody. When any pan‐TRK staining (nuclear or cytoplasmic with any staining intensity) was considered to indicate positivity, 22 of 23 SCs with ETV6-NTRK3 fusion (95.7%) and 33 of 85 non‐SC (38.8%) salivary neoplasms were positive, mainly basal cell adenoma, pleomorphic adenomas, adenoid cystic carcinomas, and epithelial-myoepithelial carcinomas. All SCs with ETV6-RET fusion were entirely negative. When only nuclear pan-TRK staining with any staining intensity was considered positive, 18 of 23 SCs with ETV6-NTRK3 fusion (78.3%) were positive, 11 among them with diffuse staining (>30% of cells). All non-SCs and SCs with ETV6-RET fusion were entirely negative. In comparison to molecular analysis (ligation-dependent reverse transcription-polymerase chain reaction, next-generation sequencing), nuclear pan-TRK IHC has a sensitivity of 78.3% and a specificity of 100% for diagnosing SCs with ETV6-NTRK3 fusion, 69% and 100% for SCs (all fusions). Pan-TRK is a reasonable screening test for diagnosing SCs among SGTs when taking only nuclear staining into account. Although pan-TRK expression is not entirely sensitive for SCs, nuclear staining is highly specific for SCs with ETV6-NTRK3 fusion. The lack of pan-TRK immunoreactivity in a subset of SCs is suggestive of atypical exons 4 to 14 or exons 5 to 14 ETV6-NTRK3 fusion or non-NTRK alternative fusion partners such as ETV6-RET. Pan-TRK staining can serve as a strong diagnostic marker to distinguish SC from it mimics and to select patients eligible for TRK inhibitor clinical trials.

show abstract

mentioning

confidence: 99%

Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors

Csanyi-Bastien¹,

Lanic

Beaussire³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…In 1992, WHO defined the OCS as “a very rare neoplasm, similar in pattern to AFS, but in which both the epithelium and mesenchymal components show cytological features of malignancy.” The terms ameloblastic carcinosarcoma and malignant odontogenic mixed tumor are synonyms of OCS. [ 7 ]…”

Section: Discussionmentioning

confidence: 99%

Odontogenic carcinosarcoma – A rare case report with review of literature

Majumdar

Uppala

Kotina

et al. 2022

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

Odontogenic carcinosarcoma (OCS) is a rare malignant odontogenic tumor (OT) with only a few cases reported in the literature. Its synonyms are ameloblastic carcinosarcoma, malignant mixed OT. It is characterized by a true mixed tumor showing malignant cytology of both epithelial and mesenchymal components. The tumor invaded into adjacent tissues by destroying the bone. A 24-year-old patient visited the outpatient clinic of GITAM Dental College and Hospital, with a chief complaint of growth in the lower right back tooth region for 6 months. Based on clinical and radiographic features, it has been diagnosed as an aggressive central jaw lesion. The patient was further referred for histological examination for confirmatory diagnosis. It has been diagnosed as an adenomatoid OT. The OCS most commonly affects the posterior part of the mandible. A larger number of cases were reported recently, and prolonged follow-up is needed to further clarify the nature of OCS.

show abstract

“…Osteomas occur commonly in the second and third decade with a male predilection. 43 On imaging, they are well demarcated tumors with central lucency. No treatment is needed unless facial deformation or morbidity occurs due to symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…No treatment is needed unless facial deformation or morbidity occurs due to symptoms. 43 After removal, they very rarely recur. 54 Osteomas comprised dense laminated bone and paucicellular fibrous stroma.…”

Section: Discussionmentioning

confidence: 99%